A Phase II, open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma (IPI-GLIO)
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms IPI-GLIO
- 25 Jan 2019 Recruitment completion is expected on 07 Jun 2020 according to ISRCTN: Current Controlled Trials record.
- 19 Nov 2018 New trial record
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.